RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study assesses the tolerability, safety, efficacy and pharmacokinetics of Bardoxolone
methyl (RTA 402) in advanced solid tumors and lymphoid malignancies.